Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Immunogenicity and Efficacy of Multiple PolyPEPI1018 Vaccinations as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer

Next Previous
X
Search
Trial Profile

Safety, Tolerability, Immunogenicity and Efficacy of Multiple PolyPEPI1018 Vaccinations as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PolyPEPI 1018 (Primary) ; Bevacizumab; Fluoropyrimidine derivatives; Montanide ISA-51
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Biomarker; First in man
  • Acronyms OBERTO
  • Sponsors Treos Bio

    • Most Recent Events

    • 26 Apr 2022 Results published in the Clinical Cancer Research
    • 31 May 2020 Final results of phase I study presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 29 May 2020 According to a Treos Bio media release, data from this study was presented at the 2020 ASCO Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top